pharmaphorum
APRIL 6, 2022
Ensuring that patients remain consistent with their therapies is one of the major challenges facing healthcare, so what if you could make treatment a game? That’s the potential behind game-based digital therapeutics and it’s drawing a lot of interest, finds Ben Hargreaves. The impact of video games on modern culture can be felt by even those that have little or no interest in them.
Outsourcing Pharma
APRIL 6, 2022
The excipients, equipment, and API companies have joined forces on Inhalation Together, an initiative aimed at advancing dry-powder inhalation solutions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 6, 2022
2021 was a big year in investment financing for US digital health companies, but there are signs that it may be a high watermark. In the first three months of this year there were 183 deals worth a total of $6 billion, giving an average size per deal of just under $33 million, according to venture fund Rock Health’s latest update on the sector.
Pharma Mirror
APRIL 6, 2022
London, ATMPS Ltd/Hataali – the leader in blockchain-based data sharing platforms for advanced therapies – announces it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of blockchain technologies in personalised medicines. The company also has applications pending in both Europe and Asia as it looks to cement its technological advantage in the rapidly growing advanced therapy space globally.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
APRIL 6, 2022
Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over the next five years, as it reinvests healthy sales revenue from Eli Lilly-partnered SGLT2 inhibitor Jardiance. The German group has just reported a 28% increase in Jardiance (empagliflozin) sales to €3.9 billion in 2021, buoyed by new approval in heart failure, which was accompanied by a 25% gain for pulmonary fibrosis therapy Ofev (nintedanib) to €2.5 billion.
Pharma Mirror
APRIL 6, 2022
GENT, BELGIUM, eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium. The upgraded R&D facility is in the Zwijnaarde Science Park, where a cluster of biotech companies are located, and includes state-of-the-art laboratories together with allied services.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Mirror
APRIL 6, 2022
New York, Kicking off the season for pharmaceutical professionals to come together digitally (09-27 May, 2022) as well as in-person (17-19 May, 2022). CPHI North America will be held as a SMART event, with three weeks of dedicated pharma learning and partnering. The benefit for the CPHI pharma community, which relies on a widening global supply chain, is that a SMART event format stimulates greater collaboration within the industry.
pharmaphorum
APRIL 6, 2022
Although resources exist for digital health entrepreneurs looking to raise their first key investment round, industry advice on next steps is harder to find. The growth of a start-up after obtaining Series A funding is a transformational phase when scaling up the company becomes critical. The CEO can experience pressure to deliver on the revenue growth goals, whilst still developing their product, growing the team, and implementing core processes for the company.
Med Ed 101
APRIL 6, 2022
In this COPD case study, we outline how to use the GOLD guidelines to guide medication therapy. Here’s the case! KE is a 71-year-old male who has a history of cigarette smoking for 50+ years, COPD, cardiovascular disease, hypertension, peripheral arterial disease, GERD, and osteoarthritis. His primary concern is his breathing and COPD. He presents […].
pharmaphorum
APRIL 6, 2022
The EU regulator has started a review of Novartis’ PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of an FDA decision on the drug due in July. Novartis said the EMA is assessing the cancer immunotherapy as a first-line treatment alongside chemotherapy for squamous or non-squamous NSCLC and as a second-line monotherapy for this type of cancer, as well as for oesophageal squamous cell carcinoma patients previously treated with che
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
APRIL 6, 2022
A technique developed by the University of Birmingham demonstrates link between patients’ alpha brain waves and responses to pain
PharmD Live
APRIL 6, 2022
By PharmD Live Staff Writer. The Social Determinants of Health in the African-American community include all of the factors of the U.S. Government’s Healthy People 2030, a set of data-driven national goals for improving health for all Americans. Included is a focus on the Merit-based Incentive Pay System (MIPS). From poverty to food insecurity and violence, the history of racism can’t be ignored as a social determinant of health today.
Pharma Times
APRIL 6, 2022
New Dublin development office will be responsible for paediatric clinical trials for seven products across 18 countries
Expert insights. Personalized for you.
111 
Let's personalize your content